SEQ
  • Bienvenido a la SEQ
    • Junta Directiva
    • Misión, visión y valores
    • Elecciones para la renovación Junta Directiva de la SEQ 2021
    • Estatutos SEQ
    • Colaboradores
    • Hazte socio
    • Contacto
  • Noticias
    • Cursos
    • Agenda de Congresos
    • Sociedades Científicas
    • Revistas Científicas
  • Actividades
    • Reuniones
    • Congresos
    • Cursos de Formación
  • Revista Española de Quimiopterapia
    • Journal info
    • Advance articles
    • Search an issue
    • Submission guidelines
    • Submit a manuscript
  • Documentos
    • Documentos de Consenso
    • Libros y monografías
    • Revista Infección y Vacunas
    • Informes
    • Declaraciones
    • Base de Datos
    • Otros
      • Curiosidades
      • Narraciones Infecciosas
  • Click to open the search input field Click to open the search input field Buscar
  • Menú Menú
Abstract 2014

Rev Esp Quimioter 2014:27(2):110-114

Report of 38 cases of tracheobronchitis in non-immunocompromised patients with dual isolation of Aspergillus in lower respiratory tract samples                                 
 

JOSE BARBERÁN, ELOY SÁNCHEZ-HAYA, DANIEL DEL CASTILLO, FRANCISCO SANZ, BERNARDINO ALCÁZAR, EDUARDO MALMIERCA, ON BEHALF OF THE ASP INVESTIGATOR GROUP               

Introduction. Aspergillus tracheobronchitis is an uncommon manifestation of Aspergillus infection. This study retrospectively analysed patients presenting tracheobronchitis among non-neutropenic/non-transplant adult patients with at least two valuable cultures of respiratory samples yielding Aspergillus spp. in Spanish hospitals.
Methods. Clinical records were retrospectively reviewed. Simple tracheobronchitis was considered when the bronchoscopy report described mucosal inflammation and mucus secretions and invasive tracheobronchitis when ulceration and pseudomembrane formation was reported. Cases were considered “proven” (histopathological confirmation) or “probable” aspergillar tracheobronchitis.
Results. A total of 38 cases of tracheobronchitis (26 simple, 12 invasive) were identified, all considered probable aspergillar tracheobronchitis. Patients were elderly (89.5% patients were ≥65 years), males (76.3%), presented advanced COPD (GOLD III+IV in 81.3%) and heart insufficiency (55.3%), with higher APACHE II score in those with invasive tracheobronchitis (10.17±7.38 vs. 4.32±4.39, p=0.019). Up to 50% patients were taking steroids (accumulated doses >100 mg in 89.5% of them) and 34.2% antibiotics pre-admission. Antifungals were administered to 60.5% patients (57.7% with simple and 66.6% with invasive tracheobronchitis). Voriconazole was the most frequent antifungal (alone or in combination): 69.6% in the 23 treated patients (60.0% simple and 87.5% invasive tracheobronchitis). Mortality was 23.7% (15.4% in simple and 41.7% in invasive tracheobronchitis).
Conclusions. The results of the present studty suggest that aspergillar tacheobronchitis should be considered in the differential diagnosis of non-immunocompromised patients with deteriorating chronic airway limitation.

Rev Esp Quimioter 2014:27(2):110-124 [pdf]

11 diciembre, 2009/por csanchez
Compartir esta entrada
  • Compartir en Facebook
  • Compartir en X
  • Compartir en LinkedIn
  • Compartir por correo
https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png 0 0 csanchez https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png csanchez2009-12-11 16:16:362009-12-11 16:16:36Rev Esp Quimioter 2014:27(2):110-114

REVISTA ESPAÑOLA DE QUIMIOTERAPIA

  • Journal Info
  • Advance Articles
  • Issues
  • Submission guidelines
  • Submit a manuscript

Contacto

Telf.: 913 94 15 12
Email: [email protected]

Política de privacidad

Aviso Legal
Política de Privacidad
Política de Cookies

Tweets by TwitterDev
© Copyright - Sociedad Española de Quimioterapia - Enfold Theme by Kriesi
  • Link to Facebook
  • Link to X
  • Link to LinkedIn
Link to: Rev Esp Quimioter 2014:27(2):110-114 Link to: Rev Esp Quimioter 2014:27(2):110-114 Rev Esp Quimioter 2014:27(2):110-114 Link to: Rev Esp Quimioter 2014:27(2):115-121 Link to: Rev Esp Quimioter 2014:27(2):115-121 Rev Esp Quimioter 2014:27(2):115-121
Desplazarse hacia arriba Desplazarse hacia arriba Desplazarse hacia arriba

Utilizamos cookies propias y de terceros para garantizar el funcionamiento de la web, medir su uso y mejorar nuestros servicios. Puede aceptar todas las cookies, rechazar las no necesarias o configurar sus preferencias. Política de cookies

Configurar cookies

Necesarias para que la web funcione correctamente. No se pueden desactivar desde este panel.

Ayudan a medir el uso del sitio y mejorar sus contenidos.

Permiten publicidad, medición de campañas o personalización de anuncios.

Guardan preferencias o permiten contenido externo no necesario.